WO2004024216A1 - 血漿浄化膜及び血漿浄化システム - Google Patents
血漿浄化膜及び血漿浄化システム Download PDFInfo
- Publication number
- WO2004024216A1 WO2004024216A1 PCT/JP2003/011715 JP0311715W WO2004024216A1 WO 2004024216 A1 WO2004024216 A1 WO 2004024216A1 JP 0311715 W JP0311715 W JP 0311715W WO 2004024216 A1 WO2004024216 A1 WO 2004024216A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- plasma
- hollow fiber
- plasma purification
- blood
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3623—Means for actively controlling temperature of blood
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
Definitions
- the present invention relates to a plasma purification membrane used for purification of plasma by internal pressure filtration and having excellent characteristics such as low clogging and high strength, and a method for producing the same.
- the present invention also relates to a plasma purification system using the plasma purification membrane and a disease treatment method.
- Hollow fiber membranes are widely used in industrial applications from microfiltration to ultrafiltration, and polyethylene, cellulose acetate, polysulfone, polyvinylidene fluoride, polycarbonate, polyacrylonitrile, etc. are used as membrane materials.
- Conventional hollow fiber membranes made of these materials have been developed with an emphasis on improving filtration performance, so the hollow fiber membranes have low breaking strength and elongation at break, and during rapid temperature changes and backwashing It has been pointed out that hollow fiber membranes often break due to changes in pressure.
- Japanese Patent No. 2 6 0 4 2 4 proposes a method for producing a membrane having high strength and excellent water permeability, but the membrane produced by this method has a large pore size, and the water permeability and fractionation performance are Unbalanced.
- JP-A-2-10 2 7 2 2 discloses that the pore diameter continuously decreases from the outer surface of the membrane to the inside, and continuously increases after passing through the minimum inner pore diameter.
- a hollow fiber microfiltration membrane that opens is disclosed. However, if a liquid or the like is filtered from the hollow portion side (inner surface side) of the membrane with this structure, it will be clogged suddenly and cannot be filtered stably for a long time.
- Japanese Laid-Open Patent Publication No. 58-155086 discloses a hollow fiber membrane having a dense layer on at least one surface of the hollow fiber membrane and a porous layer inside the hollow fiber membrane. Yes.
- a hollow fiber membrane made of a vinyl alcohol polymer is disclosed, but a membrane material made of a hydrophobic polymer and a hydrophilic polymer is not shown. If a hydrophilic polymer is included in the hydrophobic polymer, the entanglement of the molecular chains in the hydrophobic polymer is worsened, and high strength tends not to be expressed.
- the disclosed hollow fiber membrane made of a butyl alcohol polymer has a structure having a dense layer on the outer surface of the membrane, when a liquid or the like is filtered from the hollow portion side (inner surface side) of the membrane, the outer surface Filtration cannot be performed stably for a long time due to clogging in the vicinity.
- a hollow fiber membrane comprising a hydrophobic structure and a hydrophilic polymer, and having a sponge structure in which the pore diameter continuously decreases from the outer surface to the inner surface of the membrane.
- This membrane is a hemodialysis or ultrafiltration membrane that does not substantially permeate albumin, and is unsuitable for use in purifying plasma. No.5, Patent No.
- a hollow fiber membrane for purifying plasma has a desired strength, water permeability and fractionation performance in a well-balanced manner, and liquid is filtered from the hollow portion side (inner surface side).
- liquid is filtered from the hollow portion side (inner surface side).
- no product having the characteristic of no clogging was provided.
- FIG. 1 is an electron micrograph of a cross section perpendicular to the length direction of the hollow fiber membrane of the present invention (magnification: 1,500 times).
- FIG. 2 is an electron micrograph of the inner surface of the film of the present invention (magnification of 10 and 0,00 times).
- FIG. 3 is an electron micrograph of the outer surface of the film of the present invention (magnification of 10 and 0,00 times).
- FIG. 4 is a front view showing an example of the plasma purification system of the present invention.
- An object of the present invention is to provide a plasma purification membrane that is less clogged, has high strength, and has excellent water permeability and fractionation performance in plasma purification by internal pressure filtration. Furthermore, another object of the present invention is to provide a plasma purification system using such a plasma purification membrane, and a disease treatment method.
- a plasma purification membrane that is less clogged, has high strength, and has excellent water permeability and fractionation performance in plasma purification in internal pressure filtration.
- a hollow fiber membrane composed of a hydrophobic polymer and a hydrophilic polymer has a sponge structure in which the pore diameter continuously decreases from the outer surface to the inner surface of the membrane, and the breaking strength of the membrane is 50 kgf / cm 2
- a hollow fiber plasma purification membrane characterized by the above, wherein the total protein permeability when bovine plasma is filtered by internal pressure is 5,000% or more and the permeability of imnoglopurine (IgM) is 90% or less c
- the hollow fiber plasma purification membrane according to any one of the above (1) to (8), which is used for treatment of a hyperlipidemic patient.
- (1 1) The membrane-forming stock solution and the internal solution are discharged from the double annular nozzle, and then passed from the outer surface of the membrane toward the inner surface by a method for producing a hollow fiber membrane that passes through an air gap and solidifies in a coagulation bath. It consists of a sponge structure with a continuously decreasing pore size, membrane break strength of 50 kgf / cm 2 or more, and total protein permeability of 50% or more when bovine plasma is filtered with internal pressure.
- a method for producing a hollow fiber plasma purification membrane comprising a hydrophobic polymer and a hydrophilic polymer, wherein the permeability of (I g M) is 90% or less,
- the membrane forming stock solution comprises a hydrophobic polymer, a solvent for the polymer, and a hydrophilic polymer, and the ratio of the hydrophilic polymer to the hydrophobic polymer is 27 to 60% by weight,
- the internal liquid consists of water and at least one solvent, and the water content is 40 to 55% by weight,
- the temperature of the stock solution at the nozzle is 50 ° C or higher.
- the coagulation bath temperature is 90 ° to 100 ° C.
- a plasma separator containing a separation membrane for separating blood into a blood cell component and a plasma component, and a separation that separates the pathogenic substance and the plasma component from which the pathogenic substance has been removed or reduced from the separated plasma component A plasma component separator containing a membrane, and the etiology
- the membrane contained in the plasma component separator is the membrane described in any one of (1) to (10) above system.
- a method for treating a disease which comprises treating blood of a living body using the plasma purification system according to any one of (16) to (21).
- plasma purification refers to separation of components in plasma.
- albumin and ⁇ -glopurin which are useful proteins in plasma, are permeated to remove unnecessary proteins and lipids, but the components to be removed and the molecular weight cut off differ depending on the disease.
- the plasma purification of the invention broadly includes separating components in plasma.
- the hollow fiber membrane of the present invention has an integrally continuous structure from one surface of the membrane to the other surface, for example, from the inner surface to the outer surface. Between one surface of the membrane and the other surface, that is, the inside of the membrane has a network structure with a mesh size (pores) of 10 ⁇ m or less, and the size exceeds 1 ⁇ . It does not contain any polymer deficient sites (large vacancies or pores). This structure is referred to as a sponge structure in the present invention.
- the pores of the network structure inside the membrane have an inclined structure in which the pore diameter continuously decreases from the outer surface of the membrane to the inner surface (or inner surface portion) in a cross section perpendicular to the length direction of the membrane. . That is, when considering several cylindrical surfaces concentric with the central axis extending in the length direction of the hollow fiber membrane, the average pore diameter of each surface is determined from the outer surface of the membrane to the inner surface (or inner surface portion). ) As it approaches, it continuously decreases. When plasma is filtered with internal pressure, this structure is indispensable in order to achieve sharp fractionation performance (excellent protein separation).
- Fig. 1 is an electron micrograph of a cross section (part) perpendicular to the length direction of the hollow fiber membrane. Furthermore, Fig. 2 is an electron micrograph showing the state of the inner surface of the membrane, and Fig. 3 is an electron micrograph showing the appearance of the outer surface of the membrane.
- this membrane has an inclined structure in which the average pore diameter gradually decreases as it approaches the inner surface of the membrane, that is, a network structure having anisotropy with respect to the pore size.
- the inner surface of the film has a dense structure
- the film of the present invention has a clear skin layer as conventionally known. Not in. Figure 2 shows the appearance of the dense inner surface. In contrast, as can be seen from Fig. 3, circular or elliptical holes are observed on the outer surface.
- the holes that open in the inner surface of the membrane are preferably circular, elliptical, mesh-shaped or slit-shaped, and the shape of the holes on the outer surface is preferably circular or elliptical.
- the average pore diameter of the pores opened on the outer surface of the membrane is not less than ⁇ , preferably not more than 30 ⁇ . If the hole is smaller than 1 / x m, molding defects due to adhesion between films are not preferable.
- the hole area ratio of the holes on the outer surface is also important.
- the hole area ratio referred to in the present invention can be determined by digitizing an electron micrograph of the outer surface of the dried film by image analysis.
- the aperture ratio as used in the present invention is defined as a percentage of the total aperture area of the aperture portion with respect to the area of the captured image.
- Opening ratio (%) (total hole area of the opening part z area of the captured image)
- the porosity is greatly related to the contribution to the adhesion between the membranes, and if the porosity is small, the contact area between adjacent membranes increases and adhesion occurs, and in severe cases, the entire bundle is even fixed in a rod shape. is there. For this reason, it is necessary to ensure a hole area ratio of 10% or more. However, if the hole area ratio is increased unnecessarily, it will bend in the direction of the long axis of the membrane, that is, the strength of the waist will be lost, resulting in frequent molding failures due to the membrane flow at the adhesive part during molding. . Therefore, in order not to impair the waist strength, it is preferable that the upper limit of the hole area ratio is 60%.
- the shape and size of the holes opened on the surface of the membrane can be observed and measured using an electron microscope.
- the average pore diameter D of the holes opened in the inner surface and the outer surface is a value represented by the following formula (2).
- D [ ⁇ 2 + + (D n 2 ) 2 ⁇ / ⁇ Di 2 + D n 2 ⁇ ] 172 (2)
- the average hole diameter, D i is the measured diameter of the i-th hole
- D n is the measured diameter of the n- th hole.
- the measured diameters of D i and D n are expressed as the diameter when the hole is nearly circular, and when the hole is not circular, it is expressed as the diameter of a circle of the same area as the hole.
- the membrane of the present invention is a membrane having a total protein permeability of 50% or more, preferably 80% or more when bovine plasma is subjected to internal pressure filtration. If the total protein permeability is less than 50%, albumin (A lb) and ⁇ -globulin (I g G) (molecular weight of about 160,000), which are extremely effective for the human body, will be greatly lost. It is difficult to use for the treatment of patients with reduced blood pressure.
- the membrane of the present invention has a performance of immobilizing imunoglobulin (IgM) (molecular weight of about 950,000) of 90% or less when bovine plasma is subjected to internal pressure filtration.
- IgM immobilizing imunoglobulin
- albumin and ⁇ -globulin are extremely effective proteins for the human body
- high-molecular-weight proteins such as imnogrolin or lipids need to be removed depending on the disease.
- the transmittance exceeds 90%, it tends to be ineffective against diseases such as hyperlipidemia.
- the membrane of the present invention has an inclined structure in which the pore diameter continuously decreases from the outer surface to the inner surface of the membrane, and also has a large pore size that allows plasma proteins to pass through the inner surface of the membrane without any problem.
- the breaking strength of the membrane is 50 kgf / cm 2 or more, and further 6 O kgf / cm 2 or more. If the breaking strength of the membrane is less than 50 kgf / cm 2 , leaks occur frequently and it is not practical.
- the breaking strength referred to in the present invention is determined by dividing the breaking load (kgf) per hollow fiber membrane by the cross-sectional area (cm 2 ) of the membrane before pulling.
- the hollow fiber membrane of the present invention is composed of a hydrophobic polymer and a hydrophilic polymer.
- hydrophobic polymer examples include polysulfone-based polymers, polyethylene-based polymers, polypropylene-based polymers, and polyvinylidene fluoride-based polymers. From the viewpoint of forming a film by wet film formation, a polysulfone-based polymer and a polyvinylidene fluoride-based polymer are preferable.
- aromatic polysulfone has thermal stability, acid resistance and alkali resistance, It is most preferably used since the blood compatibility is improved by adding a hydrophilic polymer to the film-forming stock solution to form a film.
- aromatic polysulfone bisphenol A type polysulfone is particularly preferably used.
- the hydrophilic polymer is not particularly limited as long as it swells in water but does not dissolve in water.
- Examples thereof include a polymer having a substituent such as a quaternary ammonium group, alone or in combination of plural kinds.
- a hydrophilic polymer which is compatible with a solvent and does not dissolve a hydrophobic polymer.
- the hydrophobic polymer constituting the hollow fiber membrane is an aromatic polysulfone
- the hydrophilic polymer is most preferably polybutylpyrrolidone.
- the membrane of the present invention is most preferably composed of aromatic polysulfone and polybutylpyrrolidone. Furthermore, since the plasma purification membrane of the present invention is used by internal pressure filtration, the concentration of polyvinyl pyrrolidone on the inner surface of the membrane in contact with plasma is preferably 20 to 45% by weight. Plasma proteins are prone to hydrophobic adsorption. Therefore, an important factor for suppressing clogging in internal pressure filtration is the hydrophilicity of the inner surface of the membrane in contact with plasma. In the case of a polysulfone-based membrane containing polyvinylpyrrolidone (hereinafter also simply referred to as “PVP”), the membrane The inner surface PVP concentration is important.
- PVP polysulfone-based membrane containing polyvinylpyrrolidone
- the concentration of PVP in the case of internal pressure filtration of plasma is in the range of 20 to 45% by weight, preferably 25 to 40% by weight.
- Examples of the polysulfone-based polymer used in the present invention include those having a repeating unit represented by the following formula (3) or (4).
- Ar in the formula represents a disubstituted phenyl group at the para position, and the degree of polymerization and molecular weight are not particularly limited.
- Polyvinylpyrrolidone has a higher hydrophilic effect on the membrane with higher molecular weight.
- polybutylpyrrolidone having a weight average molecular weight of 90,000 or more is used.
- the PVP concentration on the inner surface of the film is determined by the X-ray photoelectron spectrum (X-ray photoelectron spectrum, hereinafter referred to as XPs).
- XPs X-ray photoelectron spectrum
- the polysulfone polymer has the structure of the formula (3), it can be calculated by the formula (5).
- PVP concentration (wt%) CX 1 0 0 / (C ⁇ ⁇ ⁇ + C 2 M 2 ) (5) where: Nitrogen atom concentration (%)
- the membrane of the present invention has PVP which is insoluble in water. If all PVP in the membrane is soluble in water, the amount of elution from the membrane is large, which is undesirable. If all PVP is insoluble in water, the swelling property of the inner membrane surface (or inner surface site) during plasma filtration Because it is bad, it does not exhibit excellent protein separation performance. Therefore, the membrane of the present invention has an excellent membrane performance because it appropriately contains PVP which is insoluble in water. ,
- the hollow fiber membrane of the present invention is a method for producing a hollow fiber membrane in which a membrane-forming stock solution and an internal solution are discharged from a double annular nozzle and then allowed to pass through an air gap and then coagulated in a coagulation bath.
- the membrane forming stock solution is composed of a hydrophobic polymer, a solvent for the polymer, and a hydrophilic polymer, and the ratio of the hydrophilic polymer to the hydrophobic polymer is 27 to 60% by weight,
- the internal liquid consists of water and at least one solvent, and the water content is 40 to 55% by weight,
- the temperature of the stock solution at the nozzle is 50 ° C or higher.
- the coagulation bath temperature is between 90 and 100 ° C
- the hollow fiber membrane of the present invention comprises a membrane-forming stock solution consisting essentially of a hydrophobic polymer, a solvent for the polymer, and a hydrophilic polymer, and a double layer together with an internal solution consisting of an aqueous solution having a specific concentration of a good solvent for the polymer. It is manufactured by discharging from an annular nozzle, passing through an air gap, and then solidifying in a coagulation bath.
- the solvent for the polymer include solvents such as N-methyl-2-pyrrolidone, N, N-dimethylformamide, and N, N-dimethylacetamide.
- NMP N-methyl-2-pyrrolidone
- NMP is the most solvent-soluble solvent for polysulfone polymers. For example, it has about 1.5 times the dissolving power at room temperature compared with other good solvents, N, N-dimethylacetamide.
- NMP is the best solvent for polysulfone-based polymers
- the molecular chains of the polysulfone-based polymer in the membrane-forming stock solution are well entangled, and as a result, a high-strength membrane can be obtained.
- the hydrophobic polymer is a polysulfone polymer
- Film-forming solution is essentially hydrophobic polymers, particular hydrophilic such as poly Byurupirori pyrrolidone polymers, other additives c casting dope comprising a specific solvent such as N- methyl-2 _ pyrrolidone, for example conventional additives
- a specific solvent such as N- methyl-2 _ pyrrolidone
- the hydrophobic polymer concentration of the membrane-forming stock solution used in the present invention is not particularly limited as long as the membrane can be formed from the stock solution and the obtained membrane has a membrane performance. To 35% by weight, preferably 10 to 30% by weight. In order to achieve high water permeability or a large molecular weight cut off, the polymer concentration should be low, preferably 10 to 25% by weight.
- the amount of the hydrophilic polymer in the membrane forming stock solution is 27 to 60% by weight, preferably 30 to 60% by weight.
- the blending ratio of the hydrophilic polymer to the hydrophobic polymer is less than 27% by weight, the protein permeability tends to decrease when the bovine plasma is subjected to internal pressure filtration. Is high This is not preferable because the spinnability during film formation tends to be poor.
- the temperature of the film-forming stock solution is important, and the temperature of the film-forming stock solution at the time of nozzle discharge is 50 ° C. or higher, preferably 60 to 100 ° C. If it is less than 50 ° C, the spinnability during film formation tends to be poor.
- the internal liquid is used to form the hollow portion of the hollow fiber membrane and consists of a good solvent for water and at least one hydrophobic polymer.
- the water content is preferably 40 to 55% by weight. If the water content is less than 40% by weight, the spinnability at the time of film formation is poor, and if it exceeds 55% by weight, the protein permeability tends to decrease when the bovine plasma is subjected to internal pressure filtration.
- the air gap means a gap between the nozzle and the coagulation bath.
- the ratio of the air gap (m) to the spinning speed (m / min) is extremely important. This is because the membrane structure of the present invention induces phase separation over time from the phlegm surface portion to the outer surface portion side of the membrane-forming stock solution by contact of the non-solvent in the inner solution with the membrane-forming stock solution. Further, it is because the phase separation from the inner surface portion of the membrane to the outer surface portion is not completed before the membrane-forming stock solution enters the coagulation bath.
- the ratio of the air gap to the spinning speed is preferably 0.01 to 0.1 mZ (m / min), more preferably 0.01 to 0.05 m / (m / min). .
- the ratio of the air gear to the spinning speed is less than 0 ⁇ 0 1 m / (m / min)
- the spinning speed is a series of manufacturing steps of a hollow fiber membrane in which a membrane-forming solution discharged together with an internal solution from a nozzle passes through an air gap and the membrane coagulated in a coagulation bath is scraped off. This means the removal speed when there is no stretching operation. Further, when the air gap is surrounded by a cylindrical tube or the like and a gas having a constant temperature and humidity is caused to flow through the air gap at a constant flow rate, a hollow fiber membrane can be manufactured in a more stable state.
- the coagulation bath examples include water; alcohol such as methanol and ethanol. Ethers; n (normal) Liquids that do not dissolve polymers such as aliphatic hydrocarbons such as n-hexane and n-heptane are used, but water is preferred. It is also possible to control the coagulation rate by adding a little solvent for dissolving the polymer to the coagulation bath.
- the temperature of the coagulation bath is preferably 90 to 100 ° C. If the temperature of the coagulation bath is less than 90 ° C, the protein permeability tends to decrease when the bovine plasma is subjected to internal pressure filtration, and if it exceeds 100 ° C, membrane breakage occurs frequently during film formation.
- the ratio of the film thickness to the inner diameter of the film after solidification is 0.15 to 0.4, preferably 0.2 to 0.3. If the ratio of the film thickness to the inner diameter of the film is less than 0.15, the absolute strength of the film tends to be weak. On the other hand, when the ratio exceeds 0.4, a film having an inclined structure in which the pore diameter decreases from the outer surface to the inner surface (or inner surface portion) of the film as in the present invention tends to be difficult to obtain. This is because the ratio of the amount of solvent in the film-forming stock solution to the amount of non-solvent in the internal solution is large. This is because phase separation to the outer surface site cannot be completed.
- the outer diameter of the film is 4 or less, preferably 3 100 ⁇ or less.
- the membrane area (filling amount) in the module must be reduced, and as a result, the processing capacity per unit time is inferior.
- the module container in order to increase the outer diameter of the membrane so that the membrane area (filling amount) in the module is the same, the module container must be enlarged, resulting in an increase in cost. Since the membrane of the present invention is used for medical purposes, it is necessary to avoid making an expensive large module in order to reduce the medical cost burden on the patient. From the relationship between the processing capability and the cost described above, the outer diameter of the membrane is preferably 400 ⁇ m or less.
- the membrane of the present invention can be dried. During drying, it may or may not be impregnated with a humectant such as glycerin.
- ⁇ V ⁇ in the membrane can be insolubilized in water, so the amount of elution from the membrane is reduced. Is possible. Irradiation may be either before modularization or after modularization.
- PVP that is insoluble in water is obtained by subtracting the amount of PVP that is soluble in water from the amount of PVP in the membrane.
- the total amount of PVP in the film can be easily calculated by elemental analysis of nitrogen and blue.
- the amount of PVP that is soluble in water can be determined by the following method.
- the membrane is completely dissolved with N-methyl-2-pyrrolidone, and then water is added to the obtained polymer solution to completely precipitate the hydrophobic polymer. Furthermore, after allowing the polymer solution to stand, PVP that is soluble in water can be quantified by quantifying the amount of PVP in the supernatant with a liquid chromatography.
- the plasma purification system of the present invention will be described with reference to the drawings.
- the blood supplied from the blood inlet (1) to the blood circuit (2) is pumped to the plasma separator (4) by the blood pump (3). Before introducing blood into the system, it should be sufficiently conditioned in advance by introducing a supplement such as physiological saline into the entire system. This conditioning can remove bubbles from the system.
- the plasma separator has a function of separating blood into a blood cell component and a plasma component.
- Commercially available plasma flow (Asahi Medical Co., Ltd.), Plas Makiyuichi (Kuraray Co., Ltd.), Sulfurx (Kanekuma Science Co., Ltd.), Propyrex (Ube Industries, Ltd.) Examples thereof include a filtration membrane type separator or a centrifugal type separator, but the present invention is not limited thereto.
- the plasma separated by the plasma separator is introduced into the plasma component separator (7) through the plasma circuit (5) by the plasma supply pump (6).
- Plasma is separated in a plasma component separator (7) into drainage fluid containing the etiological agent and plasma component from which the etiological agent has been removed or reduced.
- the drainage is discarded from the drainage outlet (10) via the drainage pump (9) in the drainage outlet pipe (8).
- the plasma component from which the etiological agent has been removed or reduced is supplied to a first mixing means (14) that mixes the plasma component and the capture solution.
- the replenisher is introduced from the replenisher introduction port (1 3), and is supplied to the first mixing means (14) through the replenisher introduction pipe (11) by the replenisher pump (12).
- As the first mixing means (14) for mixing the plasma component and the replenisher a tube connector or the like is used.
- the introduction of the replenisher into the system and the disposal of the drained liquid outside the system may be intermittent rather than continuous.
- the replenisher fresh frozen plasma, albumin preparation, physiological saline and the like are used.
- the plasma component supplied to the first mixing means (14) is mixed with the replenisher and then mixed with the blood cell component separated by the plasma separator (4) by the plasma recovery pump (17).
- Examples of the second mixing means for mixing the blood cell component and the plasma component include a venus chamber (Venous Chamber) and the like. 'Plasma from which etiological agents have been removed or reduced and blood cell components are mixed by the second mixing means, and the blood in the original blood state is collected from the blood outlet (16).
- the blood inlet (1) and the blood outlet (16) can be directly connected to the living body, enabling continuous treatment for a long time.
- means for warming plasma include means for directly or indirectly warming with a heater and / or warm water.
- some etiological substances separated by the plasma component separator (7) may change the removal efficiency greatly depending on the temperature, so the plasma introduced into the plasma component separator is added to the plasma component. It is also possible to maintain the target temperature by means of temperature or cooling (19). Plasma component separation due to circuit layout issues If the means for heating or cooling the plasma component cannot be arranged upstream of the vessel, the plasma component separator itself can be heated or cooled. Examples of the means for heating or cooling include means for directly or indirectly contacting cooling water and a cooler during cooling, and warm water and heater during heating. The temperature is preferably in the range of 0 to 42 ° C.
- the amount is equal to the amount of liquid supplied.
- the drainage pump (9) and the feed liquid pump (12) can be controlled.
- the balance between the drainage volume and the replenisher volume may change as the pressure distribution of the entire system changes over time, it is more preferable to control the pumps and the like of the entire system by computer.
- each pump, each mixing means, etc. can be controlled so that the supply amount and the plasma return amount returned to the second mixing means are the same.
- blood circuit plasma circuit
- various introduction pipes and lead-out pipes blood tubes such as polyvinyl chloride tubes may be used, and pulp or clamps may be used together.
- the pathogenic substance in the present invention is not limited to the following because it differs depending on the disease. If the disease is Age-related Macular Degeneration, remove pathogens such as fibrinogen (F bg) and imnoglobulin (I g M) from the blood (plasma) Or it needs to be reduced.
- F bg fibrinogen
- I g M imnoglobulin
- the disease is multiple myeloma, M protein
- the disease is primary macroglobulinemia, 0 / -Glopurin (IgG) as the etiological agent
- the disease is myasthenia gravis, anti-acetylyl receptor antibody as the etiological agent
- the disease is malignant rheumatoid arthritis Rheumatoid factor and immune complex as the etiological agent
- LD L cholesterol as the etiological agent when the disease is hyperlipidemia
- Rh blood type as the etiological agent when the disease is severe blood group incompatibility pregnancy
- Non-conforming sensitizing antibody if the disease is Giant Valley syndrome, demyelinating factor and antibody as the etiological agent, if the disease is pemphigus, anti-epidermal cell membrane antibody and IgG as the etiological agent, if the disease is pemphigus, etiology Anti-basement membrane antibody and I
- the present invention can also be applied to viral diseases, in which case the etiological agent is a virus.
- diseases such as hepatitis B, HIV, and viral leukemia can be exemplified, the present invention is not limited to these viral diseases.
- the hollow fiber membranes used as measurement samples were all dry.
- the film strength was measured using an autograph AG S-5D manufactured by Shimadzu Corporation with a sample length of 2 O mm and a pulling speed of 30 O mmZ.
- Membrane performance was evaluated by determining the concentration of each protein in the solution and plasma prior to filtration.
- the transmittance is a value represented by the following (6).
- the total protein amount (concentration) in the plasma (original solution) or the filtrate from the membrane is 0.1 mL of the solution (plasma (original solution) or the filtrate from the membrane). (Made by Co., Ltd.) 5 mL was mixed and allowed to stand for 30 minutes, and then measured with a spectrophotometer at a wavelength of 5400 nm.
- the concentration of immunoglopurin (IgM) in the plasma (original solution) or the filtrate from the membrane was measured using Beh r i n g N e p h e o l o m ter — A n aly z er B M (manufactured by Ded Behring Co., Ltd.).
- Polysnolephone (Americo Enerineering Polymers P— 1 7 0 0) 20.0 Weight 0 / o, Polyvinylpyrrolidone (BASF, Germany K 90, Weight average molecular weight 1, 2 0 0, 0 0 0) 6.0 by weight 0/0, and a uniform solvent mixture was dissolved in N- methyl-2-pyrrolidone 7 4.0 wt%.
- the mixing ratio of polyvinylpyrrolidone to polysulfone in the membrane forming stock solution was 30.0% by weight. Keep this film-forming stock solution at 60 ° C, N-methyl-2-pyrrolidone 4 6 wt% and water 5 4 wt.
- the area from the spinning nozzle to the coagulation bath was surrounded by a cylindrical tube and sealed to prevent outside air from entering.
- the spinning speed was fixed at 80 m / min.
- the ratio of the air gap to the spinning speed was 0 ⁇ 0 1 2 m / (mZ min).
- the residual solvent in the film was removed by washing with hot water shower at 80 ° C. for 2 hours from above the cut surface of the bundle.
- the membrane was further dried with hot air at 87 ° C for 7 hours to obtain a dry membrane with a water content of less than 1%.
- a portion of PVP in the film was insolubilized by irradiating the obtained dry film with 2.5 M ra d ⁇ rays.
- N-Methyl-2-pyrrolidone 5 The same procedure as in Example 1 was used, except that an internal solution consisting of a mixed solution of 4% by weight and 46% by weight of water (water content of 46% by weight) was used. I did it. Observation of the obtained film with an electron microscope revealed a sponge structure in which the pore diameter continuously decreased from the outer surface to the inner surface of the film. Table 1 shows other membrane structures and membrane performance. Breaking strength of the film showed a 5 0 kgf / c m 2 or more and high strength, the transmittance of the total protein when the bovine plasma was pressure filtration was 50% or more. In addition, bovine plasma Even in internal pressure filtration, there was no sudden clogging and a stable filtration rate was maintained for a long time.
- N-Methyl-2-pyrrolidone 5 The same procedure as in Example 1 except that an internal solution consisting of a mixed solution of 8% by weight and 42% by weight of water (water content of 42% by weight / 0 ) was used. Was done. Observation of the obtained film with an electron microscope revealed a sponge structure in which the pore diameter continuously decreased from the outer surface of the film to the surface of the ridge. Table 1 shows other membrane structures and membrane performance. The breaking strength of the membrane was as high as 50 kgf Z cm 2 or higher, and the total protein permeability was 50% or higher when bovine plasma was subjected to internal pressure filtration. In addition, the internal pressure filtration of bovine plasma maintained a stable filtration volume for a long time without sudden clogging.
- Example 1 The same operation as in Example 1 was carried out except that polybulurpyrrolidone in the film-forming stock solution was 10.0 wt% and N-methyl-2-monopyrrolidone was 70 wt%. At this time, the mixing ratio of polybutylpyrrolidone to polysulfone in the membrane forming stock solution was 50.0% by weight. When the obtained film was observed with an electron microscope, it was found that the film had a sponge structure in which the pore diameter continuously decreased from the outer surface to the inner surface. Table 1 shows other membrane structures and membrane performance. The breaking strength of the membrane was as high as 50 kgf / cm 2 or higher, and the total protein permeability when bovine plasma was filtered with internal pressure was 50% or higher. In addition, the internal pressure filtration of bovine plasma maintained a stable filtration amount for a long time without sudden clogging.
- Example 2 The same procedure as in Example 1 was carried out except that the polypyrrole pyrrolidone in the film-forming stock solution was 8.0% by weight and N-methyl-2-pyrrolidone was 70% by weight. The mixing ratio of polyvinylpyrrolidone to polysulfone in the mixture was 40.0% by weight. When the obtained film was observed with an electron microscope, the pore diameter decreased continuously from the outer surface to the inner surface of the film. 2003/011715
- Table 1 shows other membrane structures and membrane performance.
- the breaking strength of the membrane was as high as 50 kgf / cm 2 or more, and the total protein permeability when bovine plasma was filtered by internal pressure was 50% or more. Furthermore, in the internal pressure filtration of bovine plasma, there was no sudden clogging and a stable filtration volume was maintained for a long time.
- Example 2 The same procedure as in Example 1 was performed, except that an internal solution consisting of a mixed solution of N-methyl-2-pyrrolidone 4 and 3% by weight of water and 57% by weight of water (with a water content of 57% by weight) was used. It was. Observation of the obtained film with an electron microscope revealed a sponge structure in which the pore diameter continuously decreased from the outer surface to the inner surface of the film. Table 2 shows other membrane structures and membrane performance. When the bovine plasma was filtered with internal pressure, the total protein permeability was less than 50%.
- Example 2 The same operation as in Example 1 was performed except that polybulurpyrrolidone in the film-forming stock solution was changed to 5.0 wt% and N-methyl-2-pyrrolidone 75.0 wt%. At this time, the blending ratio of polybulurpyrrolidone to polysulfone in the membrane forming stock solution was 25.0 wt. /. Met. Observation of the obtained film with an electron microscope revealed that the film had a sponge structure in which the pore diameter continuously decreased from the outer surface to the inner surface. Table 2 shows other membrane structures and membrane performance. When the bovine plasma was filtered with internal pressure, the total protein permeability was less than 50%.
- Example 2 The same operation as in Example 2 was performed except that the temperature of the film forming stock solution was 45 ° C and the nozzle temperature was 45 ° C (the temperature of the film forming stock solution at the nozzle portion was 45 ° C). The film was cut frequently and could not be spun.
- Example 2 The same operation as in Example 1 was performed, except that the solvent was changed from N-methyl-2-pyrrolidone to N, N-dimethylacetamide. Observation of the obtained film with an electron microscope revealed a sponge structure in which the pore diameter continuously decreased from the outer surface to the inner surface of the film. Table 2 shows other membrane structures and membrane performance. When the bovine plasma was filtered with internal pressure, the total protein permeability was less than 50%.
- Example 1 a hollow fiber membrane having an inner diameter of 200 ⁇ ⁇ and a film thickness of 46 m obtained by the method disclosed in Example 1 of Japanese Patent Laid-Open No. Sho 5 8-15 5 8 6 5 was used. The same bovine plasma evaluation as in 1 was performed. Evaluation was interrupted because a pressure increase (clogging) occurred 120 minutes after the internal pressure filtration of the bovine plasma. [Table 1] Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples Examples
- a module with an effective membrane area of 2 m 2 was fabricated by bundling 1 1, 400 membranes of Example 1 and fixing both ends to a cylindrical housing with polyurethane resin. This module was used in a plasma component separator. Furthermore, using a plasma flow (membrane area 0.8 m 2 manufactured by Asahi Medical Co., Ltd.) as a plasma separator, human blood treatment is performed for 3 hours using an apparatus such as the system shown in FIG. It was.
- a plasma flow membrane area 0.8 m 2 manufactured by Asahi Medical Co., Ltd.
- the processing conditions are as follows.
- Blood supply to plasma separator 70 mL / min, plasma component to plasma component supply from plasma separator: 20 mL / min, drainage: 5 mLZ, capture T / JP2003 / 011715
- Liquid supply volume 5 mLZ min, temperature of plasma heating means (18): 37 ° C, temperature of plasma heating or cooling means (19): 25 ° C, replenishment As the liquid, an albumin preparation was used.
- the target blood was blood from an age-related macular degeneration patient, and the system was directly connected to the human body.
- the visual loss that changed over time stopped at the second time, and visual improvement was observed at the fourth time.
- the blood fibrinogen and imnoglopurine levels in the blood before treatment were 320 mg / dL (decylitol) and 120 mg / dL, respectively. As a result, it was apparent that the concentration was reduced to 40 mg / dL.
- the processing conditions are as follows.
- Blood supply to the plasma separator 100 mL / min
- plasma component supply from the plasma separator to the plasma component separator 40 mL / min
- drainage 5 mL / min
- Supply fluid supply volume 5 mL / min
- temperature of heating or cooling plasma (19): 20 ° C As a replenisher, an albumin preparation was used. Treatment was performed twice a week. As a result, the total cholesterol level in the blood before treatment was 560 mg Z d L (decilitre), but after treatment it was clearly reduced to 190 mg / d L. It became.
- the present invention an excellent plasma purification membrane and an excellent blood purification system that are less clogged and have high strength for plasma purification by internal pressure filtration have been obtained. Therefore, the present invention can be used for medical use, medical use, and general industrial use.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2498244A CA2498244C (en) | 2002-09-12 | 2003-09-12 | Plasma purification membrane and plasma purification system |
US10/527,802 US7563376B2 (en) | 2002-09-12 | 2003-09-12 | Plasma purification membrane and plasma purification system |
MXPA05002747A MXPA05002747A (es) | 2002-09-12 | 2003-09-12 | Membrana de purificacion de plasma y sistema de purificacion de plasma. |
AU2003261571A AU2003261571A1 (en) | 2002-09-12 | 2003-09-12 | Plasma purification membrane and plasma purification system |
EP03795429A EP1547628B1 (en) | 2002-09-12 | 2003-09-12 | Plasma purification membrane and plasma purification system |
AT03795429T ATE511868T1 (de) | 2002-09-12 | 2003-09-12 | Plasma-reinigungsmembran und plasma- reinigungssystem |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-267267 | 2002-09-12 | ||
JP2002267266A JP3431622B1 (ja) | 2002-09-12 | 2002-09-12 | 高性能血漿浄化膜 |
JP2002-267266 | 2002-09-12 | ||
JP2002267267A JP3431623B1 (ja) | 2002-09-12 | 2002-09-12 | 血漿浄化膜の製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004024216A1 true WO2004024216A1 (ja) | 2004-03-25 |
Family
ID=31996164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/011715 WO2004024216A1 (ja) | 2002-09-12 | 2003-09-12 | 血漿浄化膜及び血漿浄化システム |
Country Status (8)
Country | Link |
---|---|
US (1) | US7563376B2 (ja) |
EP (1) | EP1547628B1 (ja) |
CN (1) | CN100503020C (ja) |
AT (1) | ATE511868T1 (ja) |
AU (1) | AU2003261571A1 (ja) |
CA (1) | CA2498244C (ja) |
MX (1) | MXPA05002747A (ja) |
WO (1) | WO2004024216A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112937A1 (en) * | 2004-05-19 | 2005-12-01 | Emisphere Technologies, Inc. | Acyclovir formulations |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1875957T3 (pl) * | 2006-07-07 | 2010-09-30 | Gambro Lundia Ab | Membrana do oddzielania osocza |
ES2342966T3 (es) * | 2006-07-07 | 2010-07-20 | Gambro Lundia Ab | Membrana de separacion de plasma. |
CN102553441B (zh) * | 2006-10-18 | 2016-04-13 | 甘布罗伦迪亚股份有限公司 | 微透析装置 |
DE102007009208B4 (de) | 2007-02-26 | 2010-01-28 | Fresenius Medical Care Deutschland Gmbh | Hohlfaser, Hohlfaserbündel, Filter sowie Verfahren zur Herstellung einer Hohlfaser oder eines Hohlfaserbündels |
DE102007019051B3 (de) * | 2007-04-23 | 2008-10-09 | Fresenius Medical Care Deutschland Gmbh | Hohlfaserkapillarmembran und Verfahren zu deren Herstellung |
WO2009072548A1 (ja) * | 2007-12-06 | 2009-06-11 | Asahi Kasei Kuraray Medical Co., Ltd. | 血液処理用多孔質中空糸膜 |
ES2778726T3 (es) * | 2008-03-31 | 2020-08-11 | Toray Industries | Membrana de separación y módulo que usa la membrana de separación |
US8202240B2 (en) * | 2008-08-12 | 2012-06-19 | Caridianbct, Inc. | System and method for collecting plasma protein fractions from separated blood components |
US8123713B2 (en) * | 2008-08-12 | 2012-02-28 | Caridian Bct, Inc. | System and method for collecting plasma protein fractions from separated blood components |
ES2613267T3 (es) * | 2008-09-26 | 2017-05-23 | Asahi Kasei Kabushiki Kaisha | Membrana de fibras huecas porosa para filtración en profundidad |
US20100108599A1 (en) * | 2008-11-03 | 2010-05-06 | Kristof Vizvardi | Filtration membrane with tubular support |
JP5745510B2 (ja) | 2009-06-26 | 2015-07-08 | ビーエル・テクノロジーズ・インコーポレイテッド | 非編組式織物で強化された中空糸膜 |
EP2545986B1 (en) * | 2010-03-09 | 2020-12-09 | Toyobo Co., Ltd. | Porous hollow fiber membrane for treatment of protein-containing liquid |
KR101157514B1 (ko) * | 2010-05-28 | 2012-06-20 | 중앙대학교 산학협력단 | 두께관통형 미세기공을 가지는 고분자 또는 고분자복합재료 멤브레인 및 그 제조방법 |
US9221020B2 (en) | 2010-09-15 | 2015-12-29 | Bl Technologies, Inc. | Method to make yarn-reinforced hollow fiber membranes around a soluble core |
US8529814B2 (en) | 2010-12-15 | 2013-09-10 | General Electric Company | Supported hollow fiber membrane |
DE102011052264A1 (de) * | 2011-07-28 | 2013-01-31 | Werner Kleophas | Dialysevorrichtung sowie Verfahren zum Betreiben derselben |
CN103842003B (zh) | 2011-11-04 | 2016-10-26 | 旭化成医疗株式会社 | 血液处理用分离膜、以及安装有该膜的血液处理器 |
US9321014B2 (en) | 2011-12-16 | 2016-04-26 | Bl Technologies, Inc. | Hollow fiber membrane with compatible reinforcements |
US9643129B2 (en) | 2011-12-22 | 2017-05-09 | Bl Technologies, Inc. | Non-braided, textile-reinforced hollow fiber membrane |
WO2013093022A1 (en) | 2011-12-23 | 2013-06-27 | Universiteit Gent | Novel organosilica compounds |
US9022229B2 (en) | 2012-03-09 | 2015-05-05 | General Electric Company | Composite membrane with compatible support filaments |
US8999454B2 (en) | 2012-03-22 | 2015-04-07 | General Electric Company | Device and process for producing a reinforced hollow fibre membrane |
TWI549744B (zh) * | 2012-03-28 | 2016-09-21 | 東麗股份有限公司 | 血液製劑淨化用的聚碸系中空絲膜以及中空絲膜模組 |
US9227362B2 (en) | 2012-08-23 | 2016-01-05 | General Electric Company | Braid welding |
US9446074B2 (en) * | 2012-11-30 | 2016-09-20 | Toray Industries, Inc. | Method of preparing platelet solution replaced with artificial preservation solution |
DE102013010724A1 (de) * | 2013-06-27 | 2014-12-31 | Mann+Hummel Gmbh | Polymeres Vollbluthohlfasermembranfiltermedium und Verwendung davon zum Abtrennen von Blutplasma/-serum von Vollblut |
DE102013010735A1 (de) * | 2013-06-27 | 2015-01-15 | Mann + Hummel Gmbh | Keramisches Vollbluthohlfasermembranfiltermedium und Verwendung davon zum Abtrennen von Blutplasma/-serum von Vollblut |
US8945376B1 (en) | 2013-08-02 | 2015-02-03 | All Cell Recovery LLC | Systems, methods, and apparatus for resuspending cells in solution |
US10159980B2 (en) | 2013-08-02 | 2018-12-25 | All Cell Recovery LLC | Systems and methods for recovering blood cells, in a controlled environment, for storage |
US9452021B2 (en) | 2013-08-02 | 2016-09-27 | All Cell Recovery LLC | Systems, methods, and apparatus for resuspending cells from surgical laundry |
CN105445083B (zh) * | 2015-12-21 | 2018-09-11 | 丹娜(天津)生物科技有限公司 | 免离心全血处理模块 |
WO2018053217A1 (en) | 2016-09-16 | 2018-03-22 | Fenwal, Inc. | Blood separation systems and methods employing centrifugal and spinning membrane separation techniques |
US10391220B2 (en) | 2018-01-12 | 2019-08-27 | Fresnius Medical Care Holdings, Inc. | Virtual kidney donation |
CN109045379A (zh) * | 2018-07-12 | 2018-12-21 | 安陆恩彼饲料有限公司 | 一种血浆净化方法 |
EP3705146A3 (en) | 2019-03-05 | 2020-11-25 | Fenwal, Inc. | Collection of mononuclear cells and peripheral blood stem cells |
EP4238596A3 (en) | 2019-05-23 | 2023-12-13 | Fenwal, Inc. | Centrifugal separation and collection of red blood cells or both red blood cells and plasma |
US11484891B2 (en) | 2019-05-23 | 2022-11-01 | Fenwal, Inc. | Adjustment of target interface location between separated fluid components in a centrifuge |
CN112495596B (zh) | 2019-09-16 | 2022-07-26 | 汾沃有限公司 | 用于血液成分的分离和收集的算法的动态调整 |
AU2021304864A1 (en) | 2020-07-08 | 2023-02-23 | Fresenius Medical Care AG & Co. KGaA | Parabiotic dialysis systems and techniques |
CN113402704B (zh) * | 2021-07-09 | 2022-09-20 | 万华化学集团股份有限公司 | 一种聚碳酸酯共聚物及其制备方法和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002575A1 (fr) * | 1984-10-30 | 1986-05-09 | Teijin Limited | Membrane de fils creux a permeabilite selective, son procede de production, procede de separation de composants du plasma, et separateur de composants du plasma |
JPH043985B2 (ja) * | 1983-05-23 | 1992-01-24 | ||
WO1996014890A1 (fr) * | 1994-11-09 | 1996-05-23 | Mitsubishi Rayon Co., Ltd. | Membrane de filtration de plasma a filament creux et module de filtration de plasma |
JP3281364B1 (ja) * | 2001-07-24 | 2002-05-13 | 旭メディカル株式会社 | 血液浄化膜の製造方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1434055A (en) * | 1972-04-28 | 1976-04-28 | Asahi Chemical Ind | Hollow fibres of acrylonitrile polymers for use as an ultrafitter and method for producing the same |
JPS58155865A (ja) * | 1982-03-12 | 1983-09-16 | 株式会社クラレ | 血漿処理用中空糸膜 |
DE3584562D1 (de) * | 1984-06-13 | 1991-12-05 | Inst Nat Rech Chimique | Verfahren zur herstellung von hohlfasern und ihre verwendung in membrantrennverfahren. |
US4906375A (en) * | 1984-07-14 | 1990-03-06 | Fresenius, Ag | Asymmetrical microporous hollow fiber for hemodialysis |
DE3426331A1 (de) | 1984-07-17 | 1986-01-30 | 6380 Bad Homburg Fresenius AG | Asymmetrische mikroporoese hohlfaser fuer die haemodialyse sowie verfahren zu ihrer herstellung |
GB8505882D0 (en) * | 1985-03-07 | 1985-04-11 | Central Blood Lab Authority | Purification of blood coagulation factor viii |
JPS63105770A (ja) | 1986-10-23 | 1988-05-11 | 鐘淵化学工業株式会社 | 血漿成分分離用膜 |
JPH043985A (ja) | 1990-04-20 | 1992-01-08 | Matsushita Electric Ind Co Ltd | 発光ダイオード駆動装置 |
US5762798A (en) * | 1991-04-12 | 1998-06-09 | Minntech Corporation | Hollow fiber membranes and method of manufacture |
JP3232117B2 (ja) * | 1991-11-19 | 2001-11-26 | 鐘淵化学工業株式会社 | ポリスルホン多孔質中空糸 |
US5340480A (en) * | 1992-04-29 | 1994-08-23 | Kuraray Co., Ltd. | Polysulfone-based hollow fiber membrane and process for manufacturing the same |
EP0750938B1 (en) * | 1995-06-30 | 2005-02-16 | Toray Industries, Inc. | Manufacture of a polysulfone hollow fiber semipermeable membrane |
JP4172819B2 (ja) | 1995-12-18 | 2008-10-29 | 旭化成ケミカルズ株式会社 | 中空糸状濾過膜 |
US6074718A (en) * | 1996-02-06 | 2000-06-13 | Koch Membrane Systems, Inc. | Self supporting hollow fiber membrane and method of construction |
CN1251791C (zh) * | 1997-05-19 | 2006-04-19 | 旭医学株式会社 | 血液净化用聚砜型中空纤维膜及其制备工艺 |
WO1999047190A1 (en) * | 1998-03-16 | 1999-09-23 | Medtronic, Inc. | Hemostatic system and components for extracorporeal circuit |
US6514409B2 (en) * | 2000-02-04 | 2003-02-04 | Kuraray Co., Ltd. | Hollow fiber membrane made of an ethylene-vinyl alcohol polymer |
DE60236290D1 (de) * | 2001-07-24 | 2010-06-17 | Asahi Kasei Kuraray Medical Co | Hohlfasermembran zur reinigung von blut |
-
2003
- 2003-09-12 CN CNB038234785A patent/CN100503020C/zh not_active Expired - Lifetime
- 2003-09-12 AT AT03795429T patent/ATE511868T1/de not_active IP Right Cessation
- 2003-09-12 WO PCT/JP2003/011715 patent/WO2004024216A1/ja active Application Filing
- 2003-09-12 AU AU2003261571A patent/AU2003261571A1/en not_active Abandoned
- 2003-09-12 US US10/527,802 patent/US7563376B2/en active Active
- 2003-09-12 MX MXPA05002747A patent/MXPA05002747A/es active IP Right Grant
- 2003-09-12 EP EP03795429A patent/EP1547628B1/en not_active Expired - Lifetime
- 2003-09-12 CA CA2498244A patent/CA2498244C/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH043985B2 (ja) * | 1983-05-23 | 1992-01-24 | ||
WO1986002575A1 (fr) * | 1984-10-30 | 1986-05-09 | Teijin Limited | Membrane de fils creux a permeabilite selective, son procede de production, procede de separation de composants du plasma, et separateur de composants du plasma |
WO1996014890A1 (fr) * | 1994-11-09 | 1996-05-23 | Mitsubishi Rayon Co., Ltd. | Membrane de filtration de plasma a filament creux et module de filtration de plasma |
JP3281364B1 (ja) * | 2001-07-24 | 2002-05-13 | 旭メディカル株式会社 | 血液浄化膜の製造方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112937A1 (en) * | 2004-05-19 | 2005-12-01 | Emisphere Technologies, Inc. | Acyclovir formulations |
US8952017B2 (en) | 2004-05-19 | 2015-02-10 | Emisphere Technologies, Inc. | Acyclovir formulations |
Also Published As
Publication number | Publication date |
---|---|
AU2003261571A1 (en) | 2004-04-30 |
CA2498244C (en) | 2012-03-06 |
EP1547628A4 (en) | 2008-02-20 |
CA2498244A1 (en) | 2004-03-25 |
US7563376B2 (en) | 2009-07-21 |
CN1684727A (zh) | 2005-10-19 |
EP1547628B1 (en) | 2011-06-08 |
CN100503020C (zh) | 2009-06-24 |
MXPA05002747A (es) | 2005-06-06 |
US20060108288A1 (en) | 2006-05-25 |
ATE511868T1 (de) | 2011-06-15 |
EP1547628A1 (en) | 2005-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004024216A1 (ja) | 血漿浄化膜及び血漿浄化システム | |
CN106573203B (zh) | 多孔膜 | |
EP0294737B1 (en) | Polysulfone hollow fiber membrane and process for making the same | |
JP5074040B2 (ja) | 改良された中分子除去性を有する透析膜 | |
JP6522001B2 (ja) | 中空糸濾過膜 | |
US6042783A (en) | Hollow yarn membrane used for blood purification and blood purifier | |
JP5856821B2 (ja) | 腹水濾過濃縮装置 | |
JP5873170B2 (ja) | 高濃度タンパク質溶液の製造方法及び製造装置 | |
RU2667068C2 (ru) | Пористая мембрана, модуль очистки крови, содержащий пористую мембрану, и способ получения пористой мембраны | |
JP4265701B2 (ja) | ポリスルホン系多孔質膜 | |
AU672856B2 (en) | High flux hollow fiber membrane | |
JPH10230148A (ja) | 半透膜 | |
JP2703266B2 (ja) | ポリスルホン中空繊維膜およびその製法 | |
WO1996035504A1 (fr) | Membrane fibre creuse a base de polymere de polysulfone et son procede de production | |
JP3431622B1 (ja) | 高性能血漿浄化膜 | |
JPH09308685A (ja) | 血液浄化用中空糸膜及び血液浄化器 | |
JP4190361B2 (ja) | 中空糸型の体液処理器、これに用いる中空糸束およびそれらの製造方法 | |
JPH0211263B2 (ja) | ||
JP2001038171A (ja) | 中空糸膜 | |
JP2004098027A (ja) | 高性能精密濾過膜 | |
JP5196509B2 (ja) | 血液浄化用中空糸膜及びその製造方法 | |
JP3295314B2 (ja) | 選択透過性中空糸膜 | |
JPS60142861A (ja) | ウイルスを除去する方法 | |
JP2004098028A (ja) | 高性能中空糸状精密濾過膜の製造方法 | |
JP2008110054A (ja) | 血液浄化用中空糸膜及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003795429 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2498244 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/002747 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038234785 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003795429 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006108288 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10527802 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10527802 Country of ref document: US |